key: cord-0759123-zqzs6vtf
authors: Roman, Y. M.; Burela, P. A.; Pasupuleti, V.; Piscoya, A.; Vidal, J. E.; Hernandez, A. V.
title: Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials
date: 2021-05-25
journal: nan
DOI: 10.1101/2021.05.21.21257595
sha: abc412a2ef7c870007a0a2abd97e97d25beac05d
doc_id: 759123
cord_uid: zqzs6vtf

Background: We systematically assessed benefits and harms of the use of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint randomized controlled trials (RCTs) assessing IVM effects on COVID-19 adult patients were searched until March 15, 2021 in five engines. Primary outcomes were all-cause mortality, length of stay (LOS), and adverse events (AE). Secondary outcomes included viral clearance and severe AEs. We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse variance random effect meta-analyses were performed with quality of evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by severity of disease and RoB, and sensitivity analyses by time of follow-up were conducted. Results: Ten RCTs (n=1173) were included. Controls were standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and mild and moderate in one RCT. IVM did not reduce all-cause mortality vs. controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs, severe AE and viral clearance were similar between IVM and controls (low QoE for these three outcomes). Subgroup analyses by severity of COVID-19 disease or RoB were consistent with main analyses. Sensitivity analyses excluding RCTs with follow up <21 days showed no difference in all-cause mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison to SOC or placebo, IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease. IVM did not have effect on AEs or SAEs. IVM is not a viable option to treat COVID-19 patients.

The coronavirus disease 2019 (COVID- 19) pandemic represents a sanitary, social and economic challenge at a global level. Advances in only one year about epidemiology, prevention and clinical management on COVID-19 have been unprecedented. However, those scientific advances have also amplified deficiencies and misinformation in the scientific research environment [1] . Biological plausibility, pathophysiological considerations, in vitro research, observational studies, and/or clinical trials with heterogeneous quality have evaluated several repurposed drugs outside the scope of the initial approved medical use.

During the pandemic, some policy-makers and regulatory institutions authorized emergency use of unproven COVID-19 treatments; the use of some of these treatments has been heavily politicized in some regions of the world [2, 3] .

Ivermectin (IVM) is a semisynthetic, anthelmintic agent for oral administration. IVM is derived from the avermectins, which are isolated from the fermentation products of Streptomyces avermitilis. IVM and its analogs selectively open inhibitory glutamate-gated chloride ion channels in the membranes of pharyngeal muscles, motor nerves, female reproductive tracts, and the excretory/secretory pores of nematodes. In addition, IVM prevents the filarial ability to release substances that inhibit the host immune response [4] . In tissue cultures, at concentrations higher than anthelmintic concentrations, IVM showed antiviral (e.g., dengue), antiparasitic (e.g., malaria), and anticancer effects (e.g., epithelial ovarian cancer). However, these in vitro results have not been clinically demonstrated [4] .

In March 2020, researchers from Australia showed IVM to be active against SARS-CoV-2 in cell cultures by drastically reducing viral RNA at 48 hours [5] . Concentrations tested in these in vitro assays are equivalent to more than 50-fold the normal C max achieved with a standard single dose of IVM 200 μ g/kg, raising concerns about the effective dose of IVM for treating or preventing SARS-CoV-2 infection in humans and its tolerability [6] .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 25, 2021. ; https://doi.org/10.1101/2021.05.21.21257595 doi: medRxiv preprint However, additional theoretical considerations, experimental and observational evidence, misinformation, self-medication and the wide availability of IVM, led to its use for the treatment of COVID-19, particularly in low-and middle-income countries, assuming a priori efficacy and safety.

Ivermectin is currently approved by the Food and Drug Administration (FDA) to treat people with intestinal strongyloidiasis and onchocerciasis. The European Medicines Agency [7] and FDA [8] have not approved IVM for the treatment of COVID-19. World Health Organization (WHO) [9] and Infectious Diseases Society of America (IDSA) [ 16] or only presented on websites [17] [18] [19] .

We conducted a systematic review and meta-analysis to evaluate treatment effects of IVM on clinical outcomes and adverse events in people with COVID-19.

Two investigators (V.P., and A.V.H.) developed the search strategy, which was approved by the other investigators. We searched the following databases until March 22, 2021: PubMed-. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

We included RCTs in any language reporting benefit or harm outcomes of IVM as treatment in COVID-19 patients, both non-hospitalized and hospitalized, irrespective of COVID-19 severity. We excluded studies assessing prophylaxis for COVID-19 infection. Controls were standard of care (SOC) or placebo. Two investigators (YMR, AB) independently screened each record title and abstract for potential inclusion, and then assessed full texts of selected abstracts. Discrepancies were resolved through discussion or by a third investigator (AVH).

Primary outcomes were all-cause mortality, length of hospital stay, and adverse events (AE).

Secondary outcomes were SARS-CoV-2 clearance on respiratory samples, clinical improvement, need for mechanical ventilation, and severe adverse events (SAE). AEs and SAEs were extracted as defined by authors.

Two investigators (YMR and AB) independently extracted the following variables from studies: country(ies), sample size, dose and duration of IVM treatment, type of control group (SOC vs. placebo), COVID-19 severity, percentage of positive reverse transcription polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), study setting (hospitalized vs. non-hospitalized), mean age, proportion of female participants, co-morbidities such as hypertension, diabetes mellitus and cardiovascular . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 25, 2021. ; https://doi.org/10.1101/2021.05.21.21257595 doi: medRxiv preprint disease, evaluated outcomes, and time of follow up. COVID-19 disease severity was defined as mild, moderate or severe according to the WHO classification [19] . Discrepancies were resolved through discussion or by two other investigators (AP, AVH).

Two investigators (YMR and AB) independently assessed RoB by using the Cochrane Risk of Bias 2.0 tool for RCTs [20] ; disagreements were resolved by discussion with a third investigator (AP). The RoB 2.0 tool evaluates five domains of bias: randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported results. RoB per each of the five domains and overall were described as low, some concerns and high.

We reported our systematic review according to 2009 PRISMA guidelines [22] . Inverse variance random effect meta-analyses were performed to evaluate effect of IVM vs. control on outcomes. Effects of meta-analyses were reported as relative risks (RR) for dichotomous outcomes and as mean difference (MD) for the continuous outcome length of stay. The between study variance tau 2 was calculated with the Paule-Mandel method [23] and the 95% confidence intervals (CIs) of effects were adjusted with the Hartung-Knapp method [24] .We adjusted for zero events in one or two RCT arms using the continuity correction method [25].

Heterogeneity of effects among studies was quantified with the I 2 statistic (I 2 >60% means high heterogeneity). We pre-specified subgroup analyses by severity of COVID-19 disease and RoB; the p for interaction test <0.1 indicated effect modification by subgroup. Sensitivity analyses by excluding RCTs with shorter follow-up (i.e.<21 days) were planned for the primary outcomes. The meta package of R 3.5.1 (www.r-project.org) was used for meta-. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) analyses. The quality of evidence was evaluated using the GRADE methodology, which covers five aspects: risk of bias, inconsistency, indirectness, imprecision, and publication bias [26] . Quality of evidence (QoE) was evaluated per outcome, and described in summary of findings (SoF) tables; GRADEpro GDT was used to create SoF tables [27] .

Our search yielded 256 citations with an additional nine citations identified in pre-print web pages; 253 records were excluded. After our assessment of 12 full-texts, we identified 10 RCTs [28-37] (n=1,173) (Figure 1) . Two full-texts were excluded as there was no control group in one study, and an outcome of no interest (duration of fever) was the only one reported in another study. 

Eight RCTs were at high RoB Table 2 ).

There was no effect of IVM on severe adverse events in comparison to the controls in three RCTs (RR 1.39, 95%CI 0.36 to 5.30, I 2 =0%, low QoE) ( Figure 5 , Table 2 ) and on viral . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 25, 2021. ; 1 0 clearance in comparison to the controls in four RCTs (RR 0.96, 95%CI 0.79 to 1.16, I 2 =0%, low QoE) ( Figure 6 , Table 2 ).

Subgroup analyses by severity of COVID-19 disease or RoB were consistent with main analyses (Figures S2.1 

This systematic review provides a comprehensive overview of the current evidence for IVM effects on COVID-19 patients. In comparison to SOC or placebo, IVM did not reduce the risk of primary outcomes (all-cause mortality, length of hospital stay, and adverse events) or secondary outcomes (SARS-CoV-2 clearance in respiratory samples, and severe adverse events) in RCTs of patients with mostly mild COVID-19 disease. The quality of evidence was low or very low for all outcomes. Subgroup analyses by severity of COVID-19 disease or risk of bias were consistent with main analyses. Sensitivity analyses excluding RCTs with follow up <21 days showed no difference in all-cause mortality but diminished heterogeneity.

The findings of this study should be discussed in the context of prior published reports: two conventional systematic review and meta-analyses and two living systematic review and meta-analyses [9, [11] [12] [13] (Table S1) about IVM in COVID-19 patients with all-cause mortality as primary outcome [9] . Sixteen RCTs were evaluated, but only five directly compared IVM with SOC and reported mortality (n=915); IVM reduced all-cause mortality (OR 0.19, 95%CI 0.09-0.36). However, QoE was very low for mortality and the panel concluded that the effect of IVM on mortality was uncertain. Other outcomes (i.e. mechanical ventilation, hospital admission, and duration of hospitalization) also had very low QoE. WHO only recommended using IVM in clinical trials [9] . Siemieniuk et al. published a living systematic review and NMA about IVM in COVID-19 patients with mortality as primary outcome and other ten outcomes including hospitalization, and time to viral clearance [12] . Seven RCTs contributed to mortality assessment (n=751). IVM showed reduction of mortality (Risk difference per 1000 vs. SOC:

-103, 95%CI -117 to -78), but the QoE was very low. For other critical outcomes the QoE was low; subgroup analyses did not show differential IVM effects. This study concluded that effects of IVM were highly uncertain and there was no definitive evidence of important benefits and harms for any outcomes [12] . Taken together, the results of these four studies suggested that IVM should not be used in COVID-19 patients. Living systematic reviews . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 25, 2021. ; https://doi.org/10.1101/2021.05.21.21257595 doi: medRxiv preprint allow authors to update the evidence regularly, which is particularly important in a pandemic scenario [38] .

In addition to fully published systematic reviews, we found three pre-prints of systematic reviews [14-16] ( Table S2) and one trial registry web registry) with 1892 participants with mostly mild to moderate severity, IVM reduced mortality (aRR 0.32, 95%CI 0.14 to 0.72) [16] ; QoE was of low to moderate. Authors recommended the use of IVM in COVID-19, in particular in early disease without supporting data. The last two studies [15, 16] used very flexible research strategies and included 0 and 13% of peer-reviewed studies, respectively. In consequence, they were subject to selection bias that explain, at least in part, the effect of IVM on mortality.

Several websites published systematic reviews and meta-analyses about IVM in COVID-19 patients with unclear or absent methodology and reporting guidelines [17] [18] [19] ( Table S2) . These websites did not include protocol registration and have relevant omissions such as inclusion criteria [19] , databases searched [18, 19] , quality assessment of the included . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 25, 2021. ; https://doi.org/10.1101/2021.05.21.21257595 doi: medRxiv preprint studies [17, 19] , methods of meta-analysis [19] , and definition of heterogeneity [17, 19] .

Arbitrarily broad inclusion criteria (i.e. studies directly submitted to the websites, more preprints than peer-review studies) led to a high number of RCTs and participants. For example, a "real time meta-analysis" ivmmeta.com included 46 studies, 24 of them RCTs, and 15,480 participants [17] . Coincidentally, these three studies showed beneficial outcome effects with IVM [17] [18] [19] . In a context of misinformation infodemic, the dissemination of these results caused confusion for patients, clinicians (in particular those without training in critical reading of scientific literature), and decision-makers, which, additionally, may manipulate the information with political interests [39] .

The irrational use of IVM to treat COVID-19 patients has demonstrated several limitations in management strategies: absence of transparency by some political leaders or media in order to avoid the use of drugs without evidence of efficacy and concerns about safety; lack of decisive leadership to implementing therapeutic science-based guidelines; and misuse of both effective communication and science of communication [40] [41] [42] . Similar issues were previously experienced with hydroxychloroquine and this situation likely will be repeated in the future with other repurposed drugs. To avoid it, there is an urgent need to establish collaborative efforts among scientists, practitioners, communicators, and policymakers. A large, well-designed and -reported RCT provides the most reliable information of efficacy in the specific target population from which the sample was drawn. Similarly, a welldesigned and reported meta-analysis can provide valuable and confirmatory information [43, 44] . This condition is relevant in a pandemic where timely evaluations are needed.

Our study has several strengths. First, we performed a recent and comprehensive systematic search in five engines and unpublished studies and we did not restrict by language.

Second, we only evaluated RCTs; several previous studies included all types of designs and their findings may have been biased and confounded. Third, we evaluated outcomes with . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 25, 2021. ; https://doi.org/10.1101/2021.05.21.21257595 doi: medRxiv preprint information from at least two RCTs, including all-cause mortality, length of stay, viral clearance, adverse events and severe adverse events. No data was available for clinical improvement and need for mechanical ventilation. Fourth, we described the severity of COVID-19 disease per RCT carefully, using the WHO classification [19] ; our findings do not support the use of IVM in mild disease. Fifth, we performed subgroup analyses by risk of bias and severity of disease, which were similar to main analyses. Sixth, we also performed sensitivity analysis by excluding studies with short follow up times; effects were similar.

Finally, we evaluated the quality of evidence using GRADE methodology.

Our study also has some limitations. First, quality of evidence was low or very low for all outcomes. However, our systematic review and meta-analysis evaluated the best current available evidence and all IVM effects were negative. Second, we included only ten RCTs, five of them using a placebo as control group, and studies included a relative low number of participants. However, included RCTs are the available studies until March 15, 2021. Third, all selected RCTs evaluated patients with mild or mild to moderate COVID-19. However, the supposed benefit of IVM has been positioned precisely for mild disease, but we did not find differential IVM effects between these two severity categories. Finally, four of the RCTs had a follow-up time of only 5-10 days; analyses of primary outcomes excluding these short follow up studies showed similar IVM effects.

In conclusion, in comparison to SOC or placebo, IVM did not reduce all-cause mortality, length of stay, respiratory viral clearance, adverse events and serious adverse events in RCTs of patients with mild to moderate COVID-19. We did not find data about IVM effects on clinical improvement and need for mechanical ventilation. Additional ongoing RCTs should be completed in order to update our analyses. In the meanwhile, IVM is not a viable option to treat COVID-19 patients and only should be used within clinical trials context. In the scenario of the current COVID-19 pandemic and misinformation . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 25, 2021. ; https://doi.org/10.1101/2021.05.21.21257595 doi: medRxiv preprint infodemic, our systematic review and meta-analysis provides valuable information for clinicians, researchers, and policy-makers. ⨁ ⨁ LOW h *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; MD: Mean difference GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 25, 2021. ; .

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint 

Science during COVID-19: where do we go from here

Misguided Use of Hydroxychloroquine for COVID-19. The infusion of Politics Into Science

Political and institutional perils of Brazil's COVID-19 crisis

Ivermectin: An Anthelmintic, an Insecticide, and Much More

Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials

Hill A; International Ivermectin Project Team. Preliminary meta-analysis of randomized trials of ivermectin to treat SARSCoV-2 infection. medRxiv preprint

Ivermectin for Prevention and Treatment of COVID-19 Infection: a Systematic Review and Meta-analysis. ResearchSquare preprint

Ivermectin for COVID-19: real-time meta-analysis of 54 studies

Ivermectin reduces the risk of death from COVID-19 -a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. FLCCC Alliance

WHO Working Group on the Clinical Characterization and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research

RoB 2: a revised tool for assessing risk of bias in randomised trials

Ivermectin as a potential treatment for mild to moderate COVID-19 -A double blind randomized placebo-controlled trial

Living systematic reviews at The BMJ

Misleading clinical evidence and systematic reviews on ivermectin for COVID-19

12 Lessons learned from the management of the coronavirus pandemic

Decisive leadership is a necessity in the COVID-19 response

Misinformation about science in the public sphere

Meta-analysis: its strengths and limitations

Meta-analysis